PD Dr. Agnes Bosch

Medizinische Fakultät Department of Medicine 4 – Nephrology and Hypertension

The influence of aircraft noise exposure on the systemic and renal haemodynamics (2022) Bosch A, Kannenkeril D, Jung S, Striepe K, Karg MV, Ott C, Schmieder R Journal article Editorial comment: Renal denervation COMMENT (2021) Schmieder R, Bosch A Journal article, Editorial Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure (2021) Pietschner R, Kolwelter J, Bosch A, Striepe K, Jung S, Kannenkeril D, Ott C, et al. Journal article Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine (2021) Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, et al. Journal article Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin (2021) Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, et al. Conference contribution Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure (2021) Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, et al. Journal article Angiotensin profiles in patients with type 2 diabetes and combination therapy of empagliflozin and linagliptin versus metformin and insulin glargine (2021) Bosch A, Poglitsch M, Kannenkeril D, Ott C, Striepe K, Schmieder R Conference contribution Effect of SGLT2 inhibition on ketone bodies in patients with stable chronic heart failure (2021) Pietschner R, Kolwelter J, Bosch A, Kannenkeril D, Ott C, Schiffer M, Achenbach S, Schmieder R Conference contribution THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT IN PATIENTS WITH CHRONIC HEART FAILURE (2021) Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, et al. Conference contribution EFFECTS OF THE SGLT2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE (2021) Kolwelter J, Bosch A, Jung S, Linz P, Kannenkeril D, Nagel AM, Ott C, et al. Conference contribution